Uncontrolled activation of the innate immune system promotes the deterioration of neurons in different neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). T-cell vaccination (TCV) was developed by Irun Cohen and coworkers at the Weizmann Institute of Science (Israel) during the late 1970s and has been demonstrated to be an effective treatment for human autoimmune diseases and a regulator of macrophage activation in animal models. We treated seven ALS patients with this cell therapy and were able to slow or stop disease progression in the affected individuals. The median survival, which is 3.5 years, was extended to 6 years. They were also treated with autologous adult neural stem cells associated with effector T cells. The observed neurologic improvements after treatment lasted for at least 1 year. Clinical recovery in the treated ALS patients was confirmed by an independent, skilled neurologist using the ALS Functional Rating Scale-Revised (ALSFRS-R). TCV in conjunction with an autologous neural stem cell treatment might be a feasible, minimally invasive, safe, and effective approach to obtain enduring therapeutic effects in ALS patients.
INTRODUCTION
Injury/repair microglial function appears to play a major role in the pathogenesis of ALS (13). In a previous clinical study, we reported that T-cell vaccination Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of the central nervous system (CNS). It (TCV) treatment is capable of reestablishing control of injury/repair microglial function but failed to induce is characterized by the early apoptosis of motoneurons in the anterior horns of the spinal cord and bulb and by recovery of lost neural functions (14) . TCV is a proven immunotherapeutic approach that the subsequent destruction of motor cortex neurons (3, 7) .
The onset of ALS is associated with motor dysfunc-has been demonstrated to effectively repair the autoimmune condition through the development of organ tion, most commonly in the upper limbs and occasionally in the lower. The onset and evolution of the disease immune tolerance (24) . TCV has been successfully applied in patients with multiple sclerosis (MS) since is asymmetrical, but fatally progressing to both sides affecting all four limbs and the laryngeal and respiratory 1991. This protocol was developed during the last two decades of the 20th century by Professor Irum Cohen muscles. These last two motor impairments lead to death in 50% of patients within 2-3 years; 20% survive for 5 from the Weizmann Institute of Israel. The tolerance is primarily developed against the upregulation of spleen-years, 10% live for 10 years after onset, and a few individuals have endured 30 years of disease progression (22) . generated regulatory T cells and anti-ergotype, cytotoxic cells. Secondarily, there is a macrophage regulatory The etiology of this disease is unknown, and the pathogenesis is poorly understood. Nevertheless, we effect that supports the immune tolerance process (24) . In ALS patients, this aspect of the treatment is assumed know that some immune-mediated repair processes are activated unsuccessfully. For the past decade, a few to be the main therapeutic effect regulating the injury/ repair function of microglia (14). reports have shown that replacement of dead neurons by precommitted stem cells may partially restore lost Using the TCV program, we treated nine patients with ALS. Disease progression had completely stopped functions and improve the clinical condition of the patient (4, 12, 13, 19) .
in two of the nine patients in the previous 10 years and slowed down in five patients for 3-6 years. In the This MNC suspension was cultured for 4 days in Dulbecco's minimal essential medium enriched with a remaining two individuals, the progression of the disease followed the usual evolution of ALS.
partially hydrolyzed bovine brain and spinal cord (Laboratorios Villar, Argentina). To improve these results, the TCV treatment was complemented by a combined neural repair strategy By day 5, the activated MNCs were harvested, and immune-negative T cells were selected. Harvested cells called BEN (bone marrow mesenchymal stroma cells, effector T cells, and neuroblasts) (15, 16) .
were washed and suspended in PBS plus glycerin at 5%. Aliquots of 5 × 10 8 cells were preserved in sterile, sealed The BEN protocol is a combined cellular therapy procedure that has been successfully used to repair the spi-flasks. The flasks were irradiated with 2500 Rads to inactivate the lymphocytes and kept frozen until use. An nal cord affected by a chronic, complete functional section (15, 16) . The rationale behind this therapy is to aliquot was administered every 28 days. All of the patients were immunized by IV infusion, receiving a rebuild the prorepair immune conditions distinctive to the acute phase of CNS trauma to allow the appropriate total of 10 doses each. implant of autologous adult neuroblasts.
BEN Protocol TCV is intended to reestablish the injury/repair reaction disrupted by the progression of ALS. The BEN
The BEN protocol was applied after the third dose of TCV. The methodology has been previously published approach might then be able to replace damaged motoneurons in an enduring manner. (15, 16) . Briefly, patients underwent a bone marrow (BM) harvest, which was performed by an experienced The present article addresses the feasibility and safety of the combined TCV-BEN approach and provides an early hematologist. BM MNCs in the harvested product were purified and split into two aliquots. One aliquot was demonstration of its usefulness in treating ALS patients.
given to the patient the same day of bone marrow extraction by selective intralesion infusion into the feed-MATERIALS AND METHODS ing artery. The second aliquot was used to purify and Patients expand the included mesenchymal stromal cells (MSCs) Patients were treated at the Regina Mater Foundation for 21 days. On day 17 of the therapeutic cycle, the and the Clinic of the Maimonides University, Buenos patient underwent a leukoapheresis procedure to obtain Aires, Argentina. The treated patients met the internaa buffy coat sample corresponding to one blood volume. tionally accepted diagnostic criteria of ALS (3, 7) . They Effector T cells (ETCs) against neural tissues were isohad between 3 and 5 years of disease evolution, and lated and expanded for 4 days in the GMP cell processnone of them required mechanical respiratory assistance.
ing laboratory (17,23). Then ETCs were harvested and Each patient weighed above 40 kg. Female patients were split into two aliquots. The first one was given to the not pregnant nor breast feeding. None of the patients patient by IV infusion, and the second one was coculhad a secondary, active neoplasia, including basal cell tured with the patient's MSCs. After 48 h, the MSCs carcinoma, and none of them suffered from unstable or were differentiated into neural stem cells (NSCs) (17). compromising cardiovascular, respiratory, hepatic, or These NSCs were harvested and given to the patient by renal disease. The treated patients signed informed conselective intra-arterial infusion. During the entire cell sent forms after the nature and possible consequences of therapy cycle and thereafter, the patient received a spethe study were explained to them. cific neurorehabilitation therapy (9, 15, 16, 18, 20) .
T-Cell Vaccine Preparation Quality Control and Quality Assurance of the Cell Therapy Process
The TCV protocol has been previously described (14). Briefly, patients were apheresed using a Cobe All of the cell therapy procedures were performed by highly trained professionals in accordance with AABB Spectra cell separator machine (Gambro). Approximately 2 blood volumes were processed from each standards in a clean room that follows the GTP final rules of the FDA, Part 1271 and cGMP regulations (23) . patient using the machine's buffy coat program. The buffy coat suspension obtained had a composition of Safety Evaluations 85%; mononuclear cells (MNCs), 1.8 × 10 6 /µl red blood cells (RBCs), and 6 × 10 5 /µl platelets. To purify this Safety evaluations were performed in compliance with FDA IND regulations 21CFR 312.32. Controls MNC sample, it was seeded on a Ficoll-Hypaque gradient (1.077 density). The obtained cells were washed in were performed prior to the administration of either the TCV or BM MNCs, which was 24 h after the adminis-DBSS without Ca 2+ and Mg 2+ . After this procedure, the composition of the ring was approximately 98% MNCs, tration of the cells: on the day of the IV infusion of ETCs, which was 24 and 96 h after that infusion; and 0.2 × 10 6 /µl RBCs, and 1 × 10 4 /ml platelets. on the day of the intra-arterial infusion of NSCs, which Patient number 2 (Table 1) abandoned the treatment for family reasons unrelated to the therapy. was 24 and 96 h after that infusion. By using these controls, we monitored both early and late reactions.
Clinical Evolution Adverse events were evaluated by the "Common Terminology Criteria for Adverse Events (AE)" (2004) The individual clinical results for the seven treated patients are summarized in Table 1 . The patient median developed by the NIH. The relevant definitions are posted at http://ctep.cancer.gov/reporting/ctc.html.
survival time, as calculated by Kaplan-Meier analysis, was 72 months; however, four of the seven patients were If a severe adverse event (SAE) occurred, the treating physician, in consultation with the Internal Review alive at the end of the study. Specific tests were performed on a few patients. For Board (IRB), would determine whether the therapy would be continued (6, 23) .
patients who started cellular therapy with a diminished vital capacity (patients 1, 3, 6, and 7), an immediate Neurorehabilitation follow-up of respiratory function was performed. None of the patients worsened during the period when they The aim of neurorehabilitation is to orient cells such received TCV vaccine or BEN implant. Patients 3, 6, that they may repair the destroyed motoneurons and and 7 experienced a progression of respiratory problems neural prolongations. Therefore, a set of techniques pre-3, 4, and 12 months after completion of TCV, respecviously used for the stimulation of child neurodeveloptively. Patients 3 and 6 were not treated; they also ment was used (Vojta, Kabat, and acupuncture) (9,18).
refused to receive mechanical respiratory assistance and These techniques are similar to those that use adult inteldied. Patient 7 was treated with a second regimen of lectual capacity information (neural feedback, speech TCV and recovered his previous vital capacity. therapy, labor therapy, and psychological support).
The immune activity against spinal cord proteins detected in circulating lymphocytes progressively dimin-Clinical Evolution Assessment ished during the TCV treatment. Figure 1 illustrates the Treatment was evaluated using the ALS functional autoimmune activity against the spinal cord detected by rating scale (ALSFRS-R) (7) , which is widely used to the lymphocyte proliferation index (LPI) in patient 4. evaluate patients with ALS.
The six serial lymphoplasmaphereses abruptly decreased To complete the evaluation, complementary studies this index to a value within the normal range. There was were performed: spirometry, hand and thumb finger then a rebounding reaction that we interpret as a reactipower using an appropriate dynamometer, and immune vation of the injury/repair process (14, 22) , as this reactivity against motoneurons detected in circulating increase was not related to any clinical deterioration. blood MNCs by the lymphocyte proliferation index (14).
The LPI returned to normal values and slightly increased Physical evaluations were performed on a monthly after each BEN therapy regimen. After the treatment basis. Complementary studies were performed at the ended, the LPI abruptly increased when the disease beginning of treatment before any implant and during worsened in some of the patients. Patient 7, referred to the follow-up, every 6-12 months.
above, was re-treated with a second TCV protocol. Following this second treatment, he experienced a positive RESULTS immunological and clinical response and the disease has Safety not progressed for more than a year. The ALSFRS-R recovery that some patients experi-During the exhaustive and intensive monitoring of adverse events, nonserious, adverse events were detected enced seems to be related to the BEN administration. This clinical gain is sustained as long as the autoimmune for both the TCV or BEN treatments that were applied to the seven patients.
activity is under control. Once the autoimmune activity relapsed, clinical deterioration followed. As we demon-Adverse events were limited to flu-like symptoms that the patient would experience during the first three to strated in patient 7, this phenomenon might be reversed. four vaccines. These symptoms did not affect respiratory DISCUSSION function in any of the patients (controlled by spirometry test).
In the present report, we have demonstrated that it is feasible to treat ALS patients with a combination of two Transient reduction of the hematocrit by 1-2 points was detected after bone marrow puncture in two of the seven cellular therapy protocols: TCV and BEN. This combination is shown to be safe and, as we described in the patients. This condition did not require any treatment. Nonplatelet or white blood cell alterations were detected.
immune and clinical observations, might control both the autoimmune process involved and restore some dead Liver, didney, cardiocirculatory, and metabolic functions were not affected.
motoneurons with clinical significance. Several authors have proposed that innate immunity appears to be important to achieve an improved, longlasting neural implant, the modulation of CD4, and mac-dysfunction plays an essential role in ALS pathogenesis. CD4 and CD8 cells are also involved in the pathology rophage function, which in turn might be the key to achieving these outstanding results with this combined and the neuroprotective reaction that counteracts this disease (1, 2, 5, 8, 10, 21, 22, 25) . therapy modality (1, 2, 5, 10, 25) . The use of autologous adult cells is an additional TCV is a well-known, cellular therapeutic approach that has been shown to be effective in the restoration advantage of this approach and avoids any undesired immune effects that have been observed with the use of of self-tolerance through several different processes that include the development of an anti-ergotype, lympho-embryonic or donor neural stem cells (11). Moreover, the method to produce autologous neuroblasts from the cyte network, increasing specific regulatory T cells and macrophage modulation (24) . In a previous publication, differentiation of MSCs, induced by the ETCs (17), allows for the expansion of the MSCs until the desired we produced the first clinical evidence that TCV might be beneficial for patients with ALS (14). The present number of cells is reached. With this method, the number can be in the billions. Without the use of any recom-results support previous findings. Moreover, we also produced evidence that under some conditions, the repe-binant cytokines, coincubation with autologous ETCs provides a fast and highly efficient method of differenti-tition of this treatment may continue be effective in controlling the relapse in the long run. ation (more than 70% of the cells became neuroblasts in less than 48 h) (17). The important and long-lasting neurological recovery observed in five of the seven treated patients may be Finally, the intravascular infusion of the BEN combination is the most physiologically relevant way to implant explained by the success of BEN therapy after TCV immunomodulation. Equilibrated immune function cells, avoiding the poor distribution of local injection (14- 
